Contraindicated (one)bortezomib will increase the degree or influence of mavacamten by impacting hepatic enzyme CYP2C19 metabolism. Contraindicated. Powerful or average CYP2C19 inhibitors might enhance mavacamten systemic exposure, resulting in heart failure resulting from systolic dysfunction. Lab and/or health-related assessments (for example finish blood count) need to be accomplis... https://selisistat00987.bloginwi.com/60452022/fascination-about-2